Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H32N2O5 |
| Molecular Weight | 368.4678 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCC[C@H](N[C@@H](C)C(=O)N1[C@H]2CCCC[C@@H]2C[C@@H]1C(O)=O)C(=O)OCC
InChI
InChIKey=IPVQLZZIHOAWMC-XFIYOXNOSA-N
InChI=1S/C19H32N2O5/c1-4-8-14(19(25)26-5-2)20-12(3)17(22)21-15-10-7-6-9-13(15)11-16(21)18(23)24/h12-16,20H,4-11H2,1-3H3,(H,23,24)/t12-,13+,14-,15-,16+/m0/s1
| Molecular Formula | C19H32N2O5 |
| Molecular Weight | 368.4678 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 5 / 5 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/1457697
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1457697
(±)-2,3A-di-epi-Perindopril is a mixture of two isomers (S, SR, RR) and (R, RS, SS) which are both inactive epimers of the antihypertensive drug perindopril, although the (R, RS, SS) isomer possesses better activity.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL1808 Sources: https://www.ncbi.nlm.nih.gov/pubmed/1457697 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 23:24:01 GMT 2025
by
admin
on
Mon Mar 31 23:24:01 GMT 2025
|
| Record UNII |
3907JE47RI
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
3907JE47RI
Created by
admin on Mon Mar 31 23:24:01 GMT 2025 , Edited by admin on Mon Mar 31 23:24:01 GMT 2025
|
PRIMARY | |||
|
72941690
Created by
admin on Mon Mar 31 23:24:01 GMT 2025 , Edited by admin on Mon Mar 31 23:24:01 GMT 2025
|
PRIMARY | |||
|
145513-36-6
Created by
admin on Mon Mar 31 23:24:01 GMT 2025 , Edited by admin on Mon Mar 31 23:24:01 GMT 2025
|
PRIMARY |